Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans-Reference-Cited by-同舟云学术

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bulitta Jürgen B.¹^ORCID,Hope William W.²^ORCID,Eakin Ann E.³,Guina Tina³,Tam Vincent H.⁴,Louie Arnold⁵,Drusano George L.⁵,Hoover Jennifer L.⁶^ORCID

Affiliation:

1. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

2. Centre for Antimicrobial Pharmacodynamics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

3. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA

4. College of Pharmacy, University of Houston, Houston, Texas, USA

5. Institute for Therapeutic Innovation and Department of Medicine, College of Medicine, University of Florida, Orlando, Florida, USA

6. Antibacterial Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA

Abstract

In June 2017, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, organized a workshop entitled “Pharmacokinetics-Pharmacodynamics (PK/PD) for Development of Therapeutics against Bacterial Pathogens.” The aims were to discuss details of various PK/PD models and identify sound practices for deriving and utilizing PK/PD relationships to design optimal dosage regimens for patients. Workshop participants encompassed individuals from academia, industry, and government, including the United States Food and Drug Administration.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02307-18

Reference153 articles.

1. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

2. Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

3. Animal model pharmacokinetics and pharmacodynamics: a critical review

4. Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

5. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections;Clinical Microbiology Reviews;2024-09-12

2. Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape;Drugs;2024-09-06

3. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature;Journal of Antimicrobial Chemotherapy;2024-08-31

4. Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- Acinetobacter drug development and AMR preparedness;Antimicrobial Agents and Chemotherapy;2024-08-27

5. In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters—A Hit-to-Lead Perspective;Pharmaceuticals;2024-08-15